Secukinumab at a subcutaneous dose of 75 mg resulted in significant improvement only with a higher intravenous loading dose. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT01358175 and ...

Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov ...

Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine (Thomson Reuters ONE via COMTEX) -- Novartis ...

More than 60% of secukinumab 150mg patients achieved significant improvements in ankylosing spondylitis (AS) symptoms, seen as early as Week 1 and sustained through one year of treatment.

2014 - Novartis today announced that two pivotal Phase III studies (FUTURE 1 and FUTURE 2) of AIN457 (secukinumab) in psoriatic arthritis (PsA) met primary and key secondary endpoints.

"Novartis has recently filed global regulatory submissions for secukinumab in both psoriatic arthritis and ankylosing spondylitis and will continue to work to bring this important advance to ...

2015 – Novartis announced today new one-year study results from the MEASURE 2 pivotal Phase III study of secukinumab in ankylosing spondylitis (AS). Data from the study demonstrated that ...

Novartis has also progressed well with the development of its psoriasis candidate, secukinumab (AIN457). Recently, Novartis reported results from 2 pivotal phase III studies, FEATURE and JUNCTURE ...

after treatment with secukinumab (Cosentyx; Novartis) following relapse during a treatment pause. The new findings come from an uncontrolled, extension of the ERASURE trial, which compared ...

ZURICH (Reuters) – Results of two late-stage clinical trials showed high efficacy for Novartis’ drug secukinumab when used by patients suffering from moderate-to-severe plaque psoriasis ...

ZURICH (Reuters) – Novartis psoriasis drug secukinumab was superior to Amgen’s Enbrel in a late-stage study, the Swiss company said on Monday, putting it in line to become the first of a ...

joint regulatory filing of secukinumab in AS and PsA planned for 2015 Basel, October 23, 2014 - Novartis today announced that AIN457 (secukinumab) met primary and key secondary endpoints in two ...